Abstract
Abstract Induction therapy plays a A very important role in kidney transplantation, particularly in Living Donor Kidney Transplant (LDKT) recipients, who typically have a more favorable immunological profile. This review assesses the impact of various induction therapies, focusing on their efficacy, safety, and role in optimizing outcomes. While lymphocyte-depleting agents like Anti- Thymocyte Globulin (rATG) and alemtuzumab offer potent immunosuppression, their routine use in low-risk LDKT recipients may not be warranted. Non-depleting agents, such as basiliximab, continue to be widely used in these patients. This review explores the current evidence and strategies for personalizing induction therapy based on risk stratification and emerging biomarkers.